Short answer
Celldex Therapeutics, Inc. (CLDX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $22,000 (down 97.0% year over year) with net income of −$74M.
Q2 2026 key financials · XBRL
- Revenue
- $22,000
- −97.0% YoY · +46.7% QoQ
- Net income
- −$74M
- +33.4% YoY · +6.6% QoQ
- Operating margin
- -366468.2%
- EPS (diluted)
- −$0.93
- −9.4% YoY · +21.2% QoQ
Source: XBRL data from the Celldex Therapeutics, Inc. (CLDX) Q2 2026 10-Q on SEC EDGAR. USD.
Celldex Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Six-month R&D expense $140.543M vs $106.810M, including Barzolvolimab $117.110M vs $82.348M
- CSU Phase 3 enrollment complete; topline data expected September/October 2026, with BLA filing planned in 2027 assuming positive data
Risk Factors
- No material changes to risk factors disclosed in the February 25, 2026 Form 10-K
- No newly triggered risk factor identified during the quarter
- No updated regulatory, legal, or compliance risk disclosed
- No new operational, competitive, market, liquidity, debt, currency, or concentration risk disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Celldex Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.